Icahn School of Medicine Myeloid Malignancy Workshop 2025

• Target Audience: hematologists, oncologists
• Sample video: contact me for sample video
• Information:

Target Audience Specialties – Academic/Research, Genomic Medicine, Geriatric Medicine, Hematology, Internal Medicine, Multiple Specialties, Nurse Practitioner, Nursing, Oncology, Pathology, Pharmacist, Physician Assistant

Course Overview

This workshop will include speakers with international recognition for excellence in science and clinical care of myeloid malignancies. Given the relative rarity of each disease, rapid pace of scientific discovery over the last several years, recent approval of novel agents, and the multitude of investigational agents in late-stage clinical development it is imperative to provide cutting edge updates in a focused manner. The target audience for this CME-accredited event will include clinical and laboratory-based physicians, trainees, laboratory investigators, pharmacists, nurses, nurse practitioners, physician assistants, and patients. The event would take place in a lecture hall on the campus of Mount Sinai. The talks will be 30 minutes in duration and followed by 10-minute question and answer sessions. The event will be moderated by John Mascarenhas, Marina Kremyanskaya and Ruben Mesa and the audience will be encouraged to participate in Q&A sessions. Additionally, there will be audience response system (ARS) questions before and after to gauge impact on learning.

Objectives

Understand modern laboratory tools for exploring myeloid malignancy pathway for therapeutic targeting

Recognize the appropriate evidence-based therapies for patients with myeloid leukemia

Understand complex cellular mechanisms driving thrombosis in myeloproliferative neoplasms

Identify patient specific approaches and therapeutic options for patients with myelodysplastic syndromes

Discuss the emerging results of laboratory and clinical studies providing insights into biology and potential interventions in CHIP/CCUS

Identify treatment goals for systemic mastocytosis that incorporate next generation kit inhibitors.

The Icahn School of Medicine’s Myeloid Malignancy Workshop 2025 is best for hematologists, oncologists, clinician-scientists, fellows, and researchers focused on myeloid cancers who want cutting-edge updates on diagnostics, therapeutics, and clinical trials.

Who Should Attend

Hematologists and oncologists treating patients with AML, MDS, MPNs, and other myeloid malignancies

Fellows and residents specializing in hematology-oncology or internal medicine

Clinical researchers and translational scientists working on novel therapies and molecular targets

Pharmaceutical professionals involved in drug development for hematologic cancers

Advanced practice providers and oncology nurses supporting myeloid cancer care

What You’ll Learn

This workshop delivers focused, high-level insights into the rapidly evolving landscape of myeloid malignancies. Key highlights include:

Updates on newly approved agents and investigational therapies in late-stage development

Advances in molecular diagnostics, risk stratification, and personalized treatment

Multidisciplinary perspectives from internationally recognized experts in clinical care and research

Discussions on clinical trial design, patient selection, and outcome optimization

Networking opportunities with leaders in academic and industry settings

• Topics:

Friday, March 21, 2025